Welcome to our dedicated page for Crescent Biopharma SEC filings (Ticker: cbio), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Our SEC filing database is enhanced with expert analysis from Rhea-AI, providing insights into the potential impact of each filing on Crescent Biopharma's stock performance. Each filing includes a concise AI-generated summary, sentiment and impact scores, and end-of-day stock performance data showing the actual market reaction. Navigate easily through different filing types including 10-K annual reports, 10-Q quarterly reports, 8-K current reports, proxy statements (DEF 14A), and Form 4 insider trading disclosures.
Designed for fundamental investors and regulatory compliance professionals, our page simplifies access to critical SEC filings. By combining real-time EDGAR feed updates, Rhea-AI's analytical insights, and historical stock performance data, we provide comprehensive visibility into Crescent Biopharma's regulatory disclosures and financial reporting.
Crescent Biopharma, Inc. filed a Form S-8 to register ordinary shares for equity compensation plans following its merger and redomiciliation. The filing covers 2,345,962 shares under the 2025 Stock Incentive Plan, 195,497 shares under the 2025 Employee Stock Purchase Plan, 3,684,330 shares under the 2024 Equity Incentive Plan (for assumed options from the merger), and 1,250,000 shares under the 2025 Employment Inducement Incentive Award Plan.
The company completed a business combination with Crescent Biopharma Operating Company on June 13, 2025 and, on June 16, 2025, changed its jurisdiction of incorporation to the Cayman Islands. The filing also details director and officer indemnification provisions consistent with Cayman law and lists the relevant plan documents and consents as exhibits.
Crescent Biopharma (CBIO) filed its quarterly report for the period ended September 30, 2025. The company reported a net loss of $24.6 million for the quarter and $61.5 million year‑to‑date, driven primarily by research and development of preclinical oncology programs.
Cash and cash equivalents were $133.3 million as of September 30, 2025, and management expects this balance to fund operations for at least twelve months from the financial statement issuance date. Operating cash outflow was $44.8 million for the nine months. R&D expense was $20.3 million in Q3 ($43.1 million YTD); G&A was $5.5 million in Q3 ($18.1 million YTD).
During 2025 the company completed a reverse recapitalization with GlycoMimetics, raised capital via a pre‑closing financing, converted $37.5 million of convertible notes into equity, and redomesticated to the Cayman Islands. Shareholders’ equity improved to $116.6 million from a deficit at year‑end 2024. Ordinary shares outstanding were 13,892,516 as of November 3, 2025.
Crescent Biopharma (CBIO) furnished an 8-K announcing its financial results for the quarter ended September 30, 2025. The results are provided in a press release attached as Exhibit 99.1.
The Company states this information is being furnished under Item 2.02 and is not deemed filed for purposes of Section 18 of the Exchange Act, nor incorporated by reference except as specifically set forth. The report is signed by CEO Joshua Brumm.
Crescent Biopharma, Inc. received a Schedule 13G disclosing that Tang Capital entities and Kevin Tang together hold 700,000 ordinary shares, representing 5.04% of the outstanding class based on 13,892,562 shares. The filing breaks ownership across Tang Capital Management, LLC, Tang Capital Partners, LP (393,681 shares, 2.84%), Tang Capital Partners International, LP (306,319 shares, 2.20%), and Kevin Tang, with shared voting and dispositive power over the full position. The statement affirms the position was not acquired to change or influence control.